Outcomes of Neonates Exposed to Buprenorphine versus Methadone in Utero: A Systematic Review and Meta-Analysis of Safety in the Fetus and Neonate
We assessed the prevalence of neonatal abstinence syndrome (NAS) and fetal growth outcomes in neonates exposed to methadone compared to buprenorphine in utero. Three authors assessed the titles and abstracts of all potentially eligible studies. The selection criteria were randomized controlled trial...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Reproductive Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-3897/2/4/19 |
| _version_ | 1797500927551209472 |
|---|---|
| author | Hannah L. Christianson Alea A. Sabry Jinan E. G. Sous Jacquelyn H. Adams Kara K. Hoppe Kathleen M. Antony |
| author_facet | Hannah L. Christianson Alea A. Sabry Jinan E. G. Sous Jacquelyn H. Adams Kara K. Hoppe Kathleen M. Antony |
| author_sort | Hannah L. Christianson |
| collection | DOAJ |
| description | We assessed the prevalence of neonatal abstinence syndrome (NAS) and fetal growth outcomes in neonates exposed to methadone compared to buprenorphine in utero. Three authors assessed the titles and abstracts of all potentially eligible studies. The selection criteria were randomized controlled trials and observational cohort studies from January 2000 to January 2020 which indexed and reported original data for occurrence of NAS and fetal growth outcomes in pregnant people who received methadone vs. buprenorphine treatment. The quality and possible bias of each study was assessed using the Cochrane-risk-of-bias tool. Data were pooled to compare the occurrence of NAS and fetal growth restriction among women who received methadone vs. buprenorphine treatment. Of the 106 articles screened, 1 randomized controlled trial and 5 observational cohort studies including 2041 pregnancies fulfilled the inclusion criteria. Buprenorphine is associated with less NAS and improved growth outcomes compared to methadone. (OR = 0.515; <i>p</i>-value < 0.001). Compared to methadone, buprenorphine is associated with less adverse neonatal outcomes in terms of gestational age at birth, birthweight, and head circumference. With the prevalence of NAS continuing to rise, this study adds to the expanding academic research aimed at creating safer treatment protocols. |
| first_indexed | 2024-03-10T03:10:55Z |
| format | Article |
| id | doaj.art-b63289c0210d41e29200a922c0f11c26 |
| institution | Directory Open Access Journal |
| issn | 2673-3897 |
| language | English |
| last_indexed | 2024-03-10T03:10:55Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Reproductive Medicine |
| spelling | doaj.art-b63289c0210d41e29200a922c0f11c262023-11-23T10:26:12ZengMDPI AGReproductive Medicine2673-38972021-12-012418519410.3390/reprodmed2040019Outcomes of Neonates Exposed to Buprenorphine versus Methadone in Utero: A Systematic Review and Meta-Analysis of Safety in the Fetus and NeonateHannah L. Christianson0Alea A. Sabry1Jinan E. G. Sous2Jacquelyn H. Adams3Kara K. Hoppe4Kathleen M. Antony5Department of Microbiology, University of Wisconsin-Madison, Madison, WI 53706, USADepartment of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53715, USADepartment of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53715, USADepartment of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53715, USADepartment of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53715, USADepartment of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53715, USAWe assessed the prevalence of neonatal abstinence syndrome (NAS) and fetal growth outcomes in neonates exposed to methadone compared to buprenorphine in utero. Three authors assessed the titles and abstracts of all potentially eligible studies. The selection criteria were randomized controlled trials and observational cohort studies from January 2000 to January 2020 which indexed and reported original data for occurrence of NAS and fetal growth outcomes in pregnant people who received methadone vs. buprenorphine treatment. The quality and possible bias of each study was assessed using the Cochrane-risk-of-bias tool. Data were pooled to compare the occurrence of NAS and fetal growth restriction among women who received methadone vs. buprenorphine treatment. Of the 106 articles screened, 1 randomized controlled trial and 5 observational cohort studies including 2041 pregnancies fulfilled the inclusion criteria. Buprenorphine is associated with less NAS and improved growth outcomes compared to methadone. (OR = 0.515; <i>p</i>-value < 0.001). Compared to methadone, buprenorphine is associated with less adverse neonatal outcomes in terms of gestational age at birth, birthweight, and head circumference. With the prevalence of NAS continuing to rise, this study adds to the expanding academic research aimed at creating safer treatment protocols.https://www.mdpi.com/2673-3897/2/4/19buprenorphinemethadonefetusneonatal abstinence syndromeopioid use disorderpregnancy |
| spellingShingle | Hannah L. Christianson Alea A. Sabry Jinan E. G. Sous Jacquelyn H. Adams Kara K. Hoppe Kathleen M. Antony Outcomes of Neonates Exposed to Buprenorphine versus Methadone in Utero: A Systematic Review and Meta-Analysis of Safety in the Fetus and Neonate Reproductive Medicine buprenorphine methadone fetus neonatal abstinence syndrome opioid use disorder pregnancy |
| title | Outcomes of Neonates Exposed to Buprenorphine versus Methadone in Utero: A Systematic Review and Meta-Analysis of Safety in the Fetus and Neonate |
| title_full | Outcomes of Neonates Exposed to Buprenorphine versus Methadone in Utero: A Systematic Review and Meta-Analysis of Safety in the Fetus and Neonate |
| title_fullStr | Outcomes of Neonates Exposed to Buprenorphine versus Methadone in Utero: A Systematic Review and Meta-Analysis of Safety in the Fetus and Neonate |
| title_full_unstemmed | Outcomes of Neonates Exposed to Buprenorphine versus Methadone in Utero: A Systematic Review and Meta-Analysis of Safety in the Fetus and Neonate |
| title_short | Outcomes of Neonates Exposed to Buprenorphine versus Methadone in Utero: A Systematic Review and Meta-Analysis of Safety in the Fetus and Neonate |
| title_sort | outcomes of neonates exposed to buprenorphine versus methadone in utero a systematic review and meta analysis of safety in the fetus and neonate |
| topic | buprenorphine methadone fetus neonatal abstinence syndrome opioid use disorder pregnancy |
| url | https://www.mdpi.com/2673-3897/2/4/19 |
| work_keys_str_mv | AT hannahlchristianson outcomesofneonatesexposedtobuprenorphineversusmethadoneinuteroasystematicreviewandmetaanalysisofsafetyinthefetusandneonate AT aleaasabry outcomesofneonatesexposedtobuprenorphineversusmethadoneinuteroasystematicreviewandmetaanalysisofsafetyinthefetusandneonate AT jinanegsous outcomesofneonatesexposedtobuprenorphineversusmethadoneinuteroasystematicreviewandmetaanalysisofsafetyinthefetusandneonate AT jacquelynhadams outcomesofneonatesexposedtobuprenorphineversusmethadoneinuteroasystematicreviewandmetaanalysisofsafetyinthefetusandneonate AT karakhoppe outcomesofneonatesexposedtobuprenorphineversusmethadoneinuteroasystematicreviewandmetaanalysisofsafetyinthefetusandneonate AT kathleenmantony outcomesofneonatesexposedtobuprenorphineversusmethadoneinuteroasystematicreviewandmetaanalysisofsafetyinthefetusandneonate |